We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Emmaus Life Sciences has announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office.
Emmaus Life Sciences announced the screening of the first patient for the company's Pilot/Phase 1 study on the treatment of diverticulosis with pharmaceutical-grade L-glutamine (PGLG).